There are a number of alternative treatments available for lympoma. The following is a list of references concerning Lymphoma:
Buglio, D., et al. Histone Deacetylase Inhibitors in Hodgkin Lymphoma. Invest New Drugs. 2010 Dec;28 Suppl 1:S21-7. Department of Lymphoma/Myeloma, Houston, TX, USA. PMID: 21127943.
Buglio, D., et al. The Class-1 HDAC Inhibitor MGCD0103 Induces Apoptosis in Hodgkin Lymphoma Cell Lines and Synergizes With Protease Inhibitors by an HDAC6-Independent Mechanism. Br. J Haematol. 2010 Nov;151(4):387-96. M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA. PMID: 20880107.
Chen, D., et al. Dietary Flavonoids as Protease Inhibitors and Apoptosis in Human Leukemia Cells. Biochem Pharmacol. 2005 May 15;69(10):1421-32. Wayne State University, Detroit, MI, USA. PMID: 15857606.
Einsele, H. Bortezomib. Recent Results Cancer Res. 2010;184:173-87. University Hospital Wurzburg, Wurzburg, Germany. PMID: 20072838.
Fanale, M., et al. Phase 1 Study of Bortezomib Plus (BICE) for the Treatment of Relapsed/Refractory Hodgkin Lymphoma. Br. J Haematol. 2011 Apr 26 (Epub ahead of print.) M.D. Anderson Cancer Center, University of Texas, Houston, TX, USA. PMID: 21517809.
Gao, Y., et al. Active Hexose Correlated Compound (AHCC) Enhances Tumor Surveillance Through Regulating Both Innate and Adaptive Immune Responses. Cancer Immunol Immunother. 2006 Oct;55(10):1258-66. Yale School of Medicine, New Haven, CT, USA. (PMID: 16362410. Summary #150.)
Gardner, JM, et al. Update on Treatment of Cutaneous T-Cell Lymphoma. Curr Opin Oncol. 2009 Mar;21(2):131-7. Hospital of the Unviersity of Pennsylvania, Philadelphia, PA, USA. (PMID: 19532014. Summary #318.)
Halbsquth, TV., et al. The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma. Curr Hematol Malig Reg. 2011 May 10 (Epub ahead of print.) PMID: 21553348.
Kanwar, JR, et al. ‘Iron-Saturated’ Lactoferrin is a Potent Natural Adjuvant for Augmenting Cancer Chemotherapy. Immunol Cell Biol. 2008 Feb 12; (Epub ahead of print.) University of Auckland, Auckland, New Zealand. PMID: (18268518. Summary #349.)
Kennedy-Nasser, AA, et al. Hodgkin disease and the Role of the Immune System. Pediatr Hematol Oncol. 2011 Apr;28(3):17-86. Baylor College of Medicine, Texas Children’s Hospital, TX, USA. PMID: 21381869.
Maeda, LS., et al. Current Concepts and Controversies in the Management of Early Stage Hodgkin Lymphoma. Leuk Lymphoma. 2011 Jun:52(6):962-71. Stanford University School of Medicine, Stanford, CA, USA. PMID: 21463118.
Merlo, A., et al. Immunotherapy for EBV-Associated Malignancies. Int J Hematol. 2011 Mar;93(3):281-93. University of Padova, Padua, Italy. PMID: 21336546.
Steidl, C., et al. Molecular Pathogenesis of Hodgkin’s Lymphoma: Increasing Evidence of the Importance of the Microenvironment. J. Clin Oncol. 2011 May 10;29(14):1812-26. British Columbia Cancer Agency, Vancouver, BC, Canada. PMID: 21483001.
Waldecker, M., et al. Butyrate as a HDACi. PMID: 18061431.
Walkinshaw, DR., et al. Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics. Curr Onco. 2008 Oct;15(5):237-43. McGill Univ Health Centre, Montreal, ZC, Canada. (PMID: 19008999. Summary #317.)
Wu, YX, et al. Apigenin, Chrysin, and Luteolin Selectively Inhibit Chymotrypsin-Like and Trypsin-Like Proteasome Catalytic Activities in Tumor Cells. Planta Med. 2009 Aug 3; (Epub ahead of print.) Hamamatsu University, Hamamatsu, Japan. (PMID: 19653143. Summary #326.)
Zhao, X., et al. Bortezomib Induces Caspase-Dependent Apoptosis in Hodgkin Lymphoma Cell Lines and is Associated with Reduced c-FLIP Expression: A Gene Expression Profiling Study with Implications for Potential Combination Therapies. Leuk Res. 2008 Feb;32(2):275-85. Dept. of Clin Pathology, USA. PMID: 17659339.
Zinzani, FL, et al. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma. J. Clin Oncol. 2007 Sep 20;429307. University of Bologna, Bologna, Italy. (PMID: 17709797. Summary #275.)
Summary #497.
